Abstract: mutations are respectively rare in gastrointestinal stromal tumors (GIST). Most GIST with PDGFRA exon 18 mutations including D842V mutation are highly resistant to imatinib. The treatment of GIST harboring primary drug-resistant mutation is a major challenge. This article aims to investigate clinicopathologic features of GIST with -D842V mutation and the efficacy of comprehensive treatment, providing a reference for clinical practice. A retrospective cohort study was conducted to collect the clinicopathological and follow-up data of patients with GIST harboring mutation who were diagnosed and treated in the GIST Clinic of Renji Hospital from January 2005 to May 2020. According to the mutation site, the enrolled patients were divided into D842V mutation group and non-D842V mutation group. The differences of clinicopathologic characteristics between the two groups were compared. Furthermore, overall survival and prognostic factors were analyzed. A total of 71 patients with -mutant GIST were included in this study, including 47 cases of D842V mutation (66.2%) and 24 cases of non-D842V mutation (33.8%). There were 28 male patients and 19 female patients in D842V mutation group, with a median age of 60 (36-82) years. There were 16 male patients and 8 female patients in non-D842V mutation group, with a median age of 62 (30-81) years. There were no significant differences in age, gender, primary location, surgical procedure, tumor size, mitotic count, expression of CD117 and DOG1, Ki-67 proliferation index and modified NIH grade between the two groups (all >0.05). The positive rate of CD34 was 89.4% (42/47) and 62.5% (15/24) in the D842V mutation group and the non-D842V mutation group, respectively, with a statistically significant difference (χ(2)=5.644, =0.018). Among all the cases, 66 cases underwent R0 resection without preoperative treatment; two cases underwent emergency operation with R1 resection because of tumor rupture; 2 cases were not operated after the pathological and mutation types were confirmed by biopsy (one case received avapritinib treatment and obtain partial remission). One case was diagnosed as wild-type GIST per needle biopsy in another institute, and underwent R0 resection after preoperative imatinib treatment for 6 months. After surgery, 5 high-risk GIST patients with D842V mutation and 5 high-risk GIST patients with non-D842V mutation were treated with imatinib for more than one year. The median follow-up time was 37 (1-153) months. As of the last follow-up among the patients who received R0 resection, 4 patients with D842V mutation had relapse, of whom 1 was in the period of imatinib administration, and the 3-year relapse-free survival rate was 94.2%; none of the patients with non-D842V mutation had relapse. There was no statistically significant difference in relapse-free surivval between two groups (=0.233). Univariate analysis revealed that mitotic count (=0.002), Ki-67 proliferation index (<0.001) and modified NIH grade (=0.025) were the factors associated with relapse-free survival of patients with D842V mutation after R0 resection (all <0.05). However, the above factros were not testified as independant prognostic facors in multivariate Cox analysis (all <0.05). Clinicopathologic features and the efficacy of radical resection in patients with PDGFRA-D842V mutation are similar to those in patients with non-D842V mutation.

Structural and Biochemical Studies of the PDGFRA Kinase Domain.

An update on molecular genetics and drug resistance of gastrointestinal stromal tumors

PDGFRA alterations in cancer: characterization of a gain-of-function V536E transmembrane mutant as well as loss-of-function and passenger mutations

Neomorphic PDGFRA Extracellular Domain Driver Mutations Are Resistant to PDGFRA Targeted Therapies

Mechanism of Kinase Inactivation and Nonbinding of FRATide to GSK3β Due to K85M Mutation: Molecular Dynamics Simulation and Normal Mode Analysis.

A Novel PDGFRA Mutation in Gastrointestinal Stromal Tumours, L839P, is Sensitive to Imatinib in Vitro

Clinicopathological and Therapeutic Analysis of PDGFRA Mutated Gastrointestinal Stromal Tumor.

[Analysis of Biological Characteristics and Prognosis on Gastrointestinal Stromal Tumor with PDGFRA Gene Mutation].

Molecular Mechanism and Therapeutic Strategy for Resistance to Tyrosine Kinase Inhibitors in Targeted Treatment of Gastrointestinal Stromal Tumors

[Molecular Mechanism of Gastrointestinal Stromal Tumors and Progress in Drug Research].

Secondary Resistance to Imatinib in Patients with Gastrointestinal Stromal Tumors Through an Acquired KIT Exon 17 Mutation.

PDGFRA K385 mutants in myxoid glioneuronal tumors promote receptor dimerization and oncogenic signaling

KIT/PDGFRA inhibitors for the treatment of gastrointestinal stromal tumors: getting to the gist of the problem

[Clinicopathological features and prognosis of gastrointestinal stromal tumor with PDGFRA-D842V mutation].

Dual Targeting of Insulin Receptor and Kit in Imatinib-Resistant Gastrointestinal Stromal Tumors

[Transforming Effect of PDGFRA Gene Mutant on the Cell Function in Gastrointestinal Stromal Tumor].

Oncogenic Signaling Mechanisms in Imatinib-Resistant Gastrointestinal Stromal Tumor

Discovery and Pharmacological Characterization of AZD3229, a Potent KIT/PDGFRα Inhibitor for Treatment of Gastrointestinal Stromal Tumors

Acquired Resistance to FGFR Inhibitor in Diffuse-Type Gastric Cancer through an AKT-Independent PKC-Mediated Phosphorylation of GSK3β

PDGFRA Immunohistochemistry Predicts PDGFRA Mutations in Gastrointestinal Stromal Tumors

Structural basis of resistance of mutant RET protein-tyrosine kinase to its inhibitors nintedanib and vandetanib